Trial · NCT04079738
Adverse events61
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 61
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ADULT RESPIRATORY DISTRESS SYNDROME | Respiratory, thoracic and mediastinal disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | ALANINE AMINOTRANSFERASE INCREASED | Investigations | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | ALKALINE PHOSPHATASE INCREASED | Investigations | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | ANEMIA | Blood and lymphatic system disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 4 | 7 | 4 |
| other | ASPARTATE AMINOTRANSFERASE INCREASED | Investigations | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 2 | 7 | 2 |
| other | BACK PAIN | Musculoskeletal and connective tissue disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | BACTEREMIA | Infections and infestations | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Blood and lymphatic system disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 2 | 7 | 2 |
| other | BLOOD BILIRUBIN INCREASED | Investigations | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | BONE PAIN | Musculoskeletal and connective tissue disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 5 |
| other | BREAST PAIN | Reproductive system and breast disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 3 |
| other | CONSTIPATION | Gastrointestinal disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 2 |
| other | COUGH | Respiratory, thoracic and mediastinal disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | ECZEMA | Skin and subcutaneous tissue disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | EDEMA FACE | General disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | FEVER | General disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 2 | 7 | 3 |
| other | FLUSHING | Vascular disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | GASTROINTESTINAL DISORDERS | Gastrointestinal disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 1 | 7 | 1 |
| other | GENERALIZED EDEMA | General disorders | Phase I, Level 1: TAK-659 100mg + Ixazomid 2.3mg | 2 | 7 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04079738/events